Abiraterone acetate: Redefining hormone treatment for advanced prostate cancer

Drug Discovery Today

Volumn 17, Issue 5-6, 2012, Pages 221-226

  Pezaro, Carmel J ^a,b   Mukherji, Deborah ^a,b   De Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CYTOCHROME P450 17; DASATINIB; DEXAMETHASONE; DOCETAXEL; DUTASTERIDE; EPLERENONE; GALETERONE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; KETOCONAZOLE; ORTERONEL; OXIDOREDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SUNITINIB; TESTOSTERONE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; VT 464;

ADD ON THERAPY; ADVANCED CANCER; ADVANCED PROSTATE CANCER; APPARENT MINERALOCORTICOID EXCESS SYNDROME; BLOOD PRESSURE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CORTICOSTEROID THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; HEART DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER DISEASE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DEPLETION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84858000846     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.012     Document Type: Review

References (42)

1. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England. Office for National Statistics 2010 National Statistics London (MB1: no. 39)
2. A. Jemal Cancer statistics, 2010 CA Cancer J. Clin. 60 2010 277 300
3. Statistical Bulletin: Death Registrations by Cause in England and Wales, 2009. Office for National Statistics 2010 National Statistics London
4. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J. Urol. 168 2002 9 12
5. H. Parmar Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer Br. J. Urol. 59 1987 248 254
6. I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N. Engl. J. Med. 351 2004 1502 1512
7. J.S. de Bono Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
8. P.W. Kantoff Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med. 363 2010 411 422
9. S. Nilsson Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: combined analyses of phase I and II clinical trials ASCO Genitourinary Cancers Symposium 2010 (Abstr. 103)
10. C. Parker Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer: a phase III randomised trial ECCO-ESMO Annual Congress 11 Stockholm, Sweden 2011 (Abstr. LBA1)
11. J.S. de Bono Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
12. B.A. Hellerstedt, and K.J. Pienta The current state of hormonal therapy for prostate cancer CA Cancer J. Clin. 52 2002 154 179
13. J. Trachtenberg Ketoconazole therapy in advanced prostatic cancer J. Urol. 132 1984 61 63
14. I. Schuster, and R. Bernhardt Inhibition of cytochromes p450: existing and new promising therapeutic targets Drug Metab. Rev. 39 2007 481 499
15. G. Lake-Bakaar Hepatic reactions associated with ketoconazole in the United Kingdom Br. Med. J. (Clin. Res. Ed.) 294 1987 419 422
16. S.E. Barrie Highly potent inhibitors of human cytochrome P-450 (17α): activity in vitro and in vivo Br. J. Cancer 67 1993 (Abstr. P177)
17. G.A. Potter Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer J. Med. Chem. 38 1995 2463 2471
18. S.E. Barrie Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase) J. Steroid Biochem. Mol. Biol. 50 1994 267 273
19. D.R. Newell Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK Br. J. Cancer 89 2003 437 454
20. A. O'Donnell Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br. J. Cancer 90 2004 2317 2325
21. G. Attard Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J. Clin. Oncol. 26 2008 4563 4571
22. C.J. Ryan Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J. Clin. Oncol. 28 2010 1481 1488
23. G. Attard Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 27 2009 3742 3748
24. C.J. Ryan Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response Clin. Cancer Res. 17 2011 4854 4861
25. G.M. Sundkvist Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy Eur. J. Nucl. Med. 16 1990 671 676
26. W.D. Johns Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan Clin. Nucl. Med. 15 1990 485 487
27. H.I. Scher Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J. Clin. Oncol. 26 2008 1148 1159
28. D.C. Danila Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J. Clin. Oncol. 28 2010 1496 1501
29. A.H. Reid Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J. Clin. Oncol. 28 2010 1489 1495
30. H.I. Scher Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus prednisone (P) post docetaxel J. Clin. Oncol. 29 2011 (Suppl. Abstr. LBA4517)
31. M. Yu Circulating tumor cells: approaches to isolation and characterization J. Cell Biol. 192 2011 373 382
32. W.J. Allard Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin. Cancer Res. 10 2004 6897 6904
33. J.S. de Bono Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin. Cancer Res. 14 2008 6302 6309
34. A. Horwich Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 21 Suppl. 5 2010 129 133
35. A.H. Reid Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br. J. Cancer 102 2010 678 684
36. G. Attard Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res. 69 2009 2912 2918
37. D.C. Danila TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate Eur. Urol. 60 2011 897 904
38. C. Ryan Abiraterone in prostate cancer Clin. Adv. Hematol. Oncol. 8 2010 761 762
39. O. Sartor Combination therapy: abiraterone prolongs survival in metastatic prostate cancer Nat. Rev. Clin. Oncol. 8 2011 515 516
40. R. Dreicer Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study 2010 Genitourinary Cancers Symposium 2010 (Abstr. 103)
41. C. Cai Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate prostate cancer & is upregulated by treatment with CYP17A1 inhibitors Cancer Res. 71 2011 6503 6513
42. E.A. Mostaghel Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis & androgen receptor splice variants Clin. Caner Res. 17 2011 5913 5925